Insights into the potential role of alpha1-antitrypsin in COVID-19 patients: Mechanisms, current update, and future perspectives

Clin Respir J. 2021 Sep;15(9):1019-1024. doi: 10.1111/crj.13406. Epub 2021 Jul 12.

Abstract

In this work, we provide an up-to-date summary of the available molecular- and cell-related mechanisms by which alpha1-antitrypsin (AAT) protein could be of benefit in treating COVID-19 patients. As well, we demonstrate the current status in terms of the ongoing clinical trials using AAT in COVID-19 patients. Finally, we touch on the potential role gene therapy and stem cell-based gene therapy could have in such emerging and serious condition caused by the SARS-CoV-2 virus.

MeSH terms

  • COVID-19*
  • Humans
  • SARS-CoV-2
  • alpha 1-Antitrypsin / genetics
  • alpha 1-Antitrypsin Deficiency* / genetics
  • alpha 1-Antitrypsin Deficiency* / therapy

Substances

  • alpha 1-Antitrypsin